1.. Introduction {#s0001}
================

Carbonic anhydrases (CAs; EC 4.2.1.1) are metalloproteins present virtually in all living organisms. CA enzymatic activity was first observed in the early 1930s, when experiments performed with hemolyzed blood samples have demonstrated that the rate of carbon dioxide release from the hemolyzed blood was higher than expected, indicating that blood could contain a catalyst for the dehydration of bicarbonate, which allows the formation of CO~2~ \[[@CIT0001]\]. This catalyst, named carbonic anhydrase, was thereafter extracted from erythrocytes in 1933 by Meldrum and Roughton \[[@CIT0002]\]. Upon the discovery in 1940 that zinc ions are an intrinsic cofactor of the protein, CA became the first recognized metalloenzyme. This enzyme efficiently catalyzes the reversible hydration of carbon dioxide (CO~2~) to yield bicarbonate (HCO~3~^-^) and protons (H^+^) \[[@CIT0002],[@CIT0003]\]. $$\left. \text{CO}_{\text{2}} + \text{~H}_{\text{2}}\text{O}~\rightleftharpoons~\text{HCO}_{\text{3}}{}^{-} + \text{~H}^{+} \right.$$

It has been known since the 1940s that CA is ubiquitous in plants \[[@CIT0004]\], where it performs an essential role in CO~2~ fixation \[[@CIT0005]\]. CAs, under the form of many enzyme families and isoforms, are virtually found in all living organisms, from the unicellular ones to higher vertebrates including humans. Their structure is encoded by eight evolutionary unrelated gene families, leading thus to the α-, β-, γ-, δ-, ζ-, η-, Θ-, and ι-CA classes \[[@CIT0006]\]:α-CAs are Zn^2+^ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa and plants \[[@CIT0009]\].β-CAs are Zn^2+^ metalloproteins present in bacteria, plants, fungi, chloroplasts of mon-/dicotyledons \[[@CIT0006]\].γ-CAs are Zn^2+^ or Fe, Co metalloproteins present in some plants, fungi, bacteria and archarea \[[@CIT0006]\].δ-CAs are Co metalloproteins present in marine diatoms \[[@CIT0007],[@CIT0010]\].ζ-CAs are Cd or Zn metalloproteins identified only in some marine diatoms \[[@CIT0011]\].η-CA are Zn metalloproteins identified in Plasmodium spp. \[[@CIT0012]\].Θ-CA are Zn metalloproteins identified in Marine diatoms \[[@CIT0011]\].ι-CAs were only recently reported to be present in diatoms and bacteria and seem to be Mn(II) proteins \[[@CIT0013]\].

CA inhibitors (CAIs) targeting mammalian CAs, are in clinical use as diuretics, antiglaucoma, antiepileptic or antiobesity agents for decades \[[@CIT0003],[@CIT0006],[@CIT0014]\]. These diverse applications are due to the fact that at least 15 different α-CA isoforms are present in humans, being involved in critical physiological and pathological processes \[[@CIT0014]\].

In the current review, we focused our attention on recent activation studies on α-, β-, γ-, δ-, ζ-, and η-CA classes which were explored with at least two classes of modulators of activity, amines and amino acids. The catalytic mechanism of these enzymes is in fact well understood \[[@CIT0003]\]. A metal hydroxide species present in the active site of these enzymes as the fourth ligand ([Figure 1(A,B)](#F0001){ref-type="fig"}) acts as a strong nucleophile (at physiologic pH) converting the CO~2~ to bicarbonate, bis-coordinated to Zn(II), in a trigonal bipyramidal geometry ([Figure 1(C))](#F0001){ref-type="fig"}. This adduct is not very stable and reaction with a water molecule leads to liberation of bicarbonate in solution and generation of an acidic form of the enzyme incorporating a M^2+^(OH~2~) species at the metal center, which is catalytically ineffective for the hydration of CO~2~ ([Figure 1(D))](#F0001){ref-type="fig"}. In order to generate the nucleophilic, M ^2+^(OH^\_^) species, a proton transfer reaction occurs, which is rate determining for the catalytic cycle in many of these quite rapid enzymes. CA enzymes typically use a metal ion (Zn^2+^ in α-, β- and γ-CAs, Fe^2+^/Co^2+^/Zn^2+^) which favors in the reduction pKa of H~2~O from 14 to 7 \[[@CIT0006]\]. Human CAs use a Zn^2+^ ion to decrease the pKa of H~2~O bound with Zn^2+^ ion which also binds to histidine residues (His94, His96 and His119). For many α-CAs this step is assisted by a proton shuttle residue, which is His64 in most mammalian isoforms. Possessing a flexible orientation, inwards (the *in* conformation) or outwards (the *out* conformation) the zinc ion center, the imidazole moiety of this histidine, with a pKa of 6.0--7.5 is an appropriate proton shuttling residue and crucially important for the entire catalytic cycle. The process can be also assisted by endogenous molecules, which bind within the enzyme active site (as proven by X-ray crystallography and other techniques) which have been termed CA activators (CAAs) \[[@CIT0019]\]. They facilitate the proton transfer reactions between the metal ion center and the external medium. It was understood that CA activators act by speeding up the deprotonation of zinc-bound water (the rate-determining step, [Equation (2)](#M0003){ref-type="disp-formula"} in the catalytic mechanism) \[[@CIT0019]\], with the generation of the active form of the enzyme \[[@CIT0022]\] (see equations below): $$\left. EZn^{2 +} - OH^{-} + CO_{2}{}\rightleftharpoons EZn^{2 +} - HCO_{3}{}^{-}\overset{+ H_{2}O}{\rightleftharpoons}EZn^{2} - OH_{2} + HCO_{3}{}^{-}\,\,\, \right.$$ $$\left. EZn^{2 +} - OH_{2}{}\,\rightleftharpoons\, EZn^{2 +} - OH^{-} + H^{+}\,\,\,\,\, - rate\, determining\, step - \,\,\, \right.$$

![Catalytic mechanism of α-CAs \[[@CIT0003]\]. A. The zinc hydroxide form of the enzyme. B. The bucleophilic attack on CO2 bound in the hydrophobic pocket. C. Bicarbonate bound to the active site metal ion. D. Acidic form of the enzyme. B in the last step of the cycle is a buffer molecule or the imidazole moiety of a His64 residue from the enzyme active site, acting as proton shuttle.](IENZ_A_1664501_F0001_C){#F0001}

In the presence of an activator 'A', [Equation (2)](#M0003){ref-type="disp-formula"} becomes ([3](#M0004){ref-type="disp-formula"}): $$\left. \text{EZn}^{\text{2} +} - \text{OH}_{\text{2}} + \text{~A}\rightleftharpoons\lbrack\text{EZn}^{\text{2} +} - \text{OH}_{\text{2}} - \text{~A}\rbrack~\rightleftharpoons~\lbrack\text{EZn}^{\text{2} +} - \text{HO}^{-} - \text{~AH}^{+}\rbrack~\rightleftharpoons~\text{EZn}^{\text{2} +} - \text{HO}^{-} + \text{~AH}^{+} \right.$$

enzyme - activator complexes

CAAs may have pharmacologic applications, activation of the mammalian enzymes was shown to enhance cognition and memory in experimental animals \[[@CIT0023]\], likewise its inhibition has an opposite effect \[[@CIT0024]\].

In order to better understand the catalytic mechanism of CAs belonging to the β-, δ- γ-, δ- ζ-, η-CA and Θ-CA classes, it is of crucial importance to see if these enzymes act, similar to the α-CAs, which can be activated by compounds that shuttle protons between the active site and the environment. The activation of CAs from pathogenic bacteria may be relevant for understanding the factors governing virulence and colonization of the host, because pH in the tissues surrounding the pathogens likely plays a key role in such processes and many compounds that are CAAs (biogenic amines and amino acid derivatives) are abundant in such tissues. In this review, we have carefully analyzed the activation potential of different natural, non natural, aromatic/heterocyclic amino acids and amines (compounds **1--19**) across 6 different families of CAs that were investigated based on the existing literature ([Chart 1](#F0002){ref-type="fig"}) \[[@CIT0019]\]. These compounds have functional groups similar to their endogenous proton shuttlers, and can participate in proton transfer processes during the catalytic cycle. This study is relevant as no X-ray crystal structures of enzyme activator complexes have been reported so far for β- γ-, δ-, ζ-, η-CA and Θ-CAs.

![Amino acids **1--11** and amines **12--19**.](IENZ_A_1664501_F0002_C){#F0002}

2.. Activation of α-CAs with amino acids and amines {#s0002}
===================================================

Activation of the twelve catalytically active human (h) or murine (m) CA isoforms, hCA I, hCA II, hCA III, hCA IV, hCA VA, hCA VB, hCA VII, hCA IX, hCA XII, mCA XIII, hCA XIV and mCA XV with amino acids and amines (**1--19**) has been investigated by stopped flow CO~2~ hydrase assay method and are shown in [Table 1](#t0001){ref-type="table"} \[[@CIT0025]\]. This bioassay is in excellent agreement with results from native mass spectrometry \[[@CIT0030]\]. The following structure-activity relationship (SAR) can be summarized from data presented in [Table 1](#t0001){ref-type="table"} based on the activation profile of these derivatives.

###### 

*In vitro* hCA I \[[@CIT0025]\], hCA II \[[@CIT0025]\], hCA III \[[@CIT0026]\], hCA IV \[[@CIT0026]\], hCA VA \[[@CIT0027]\], hCA VB \[[@CIT0027]\], hCA VII \[[@CIT0028]\], hCA IX \[[@CIT0029]\], hCA XII \[[@CIT0029]\], mCA XIII \[[@CIT0025]\], hCA XIV \[[@CIT0028]\] and mCA XV \[[@CIT0030]\] activation data with amines and amino acids (**1--19**) by a stopped-flow CO~2~ hydrase assay.

                                          K~A~ (µM)[^a^](#TF1){ref-type="table-fn"}                                                                                  
  -------- ------------------------------ ------------------------------------------- ------- ------- ------- ------- ------- ------- ------- ------ ------- ------- ------
  1        L-His                          0.03                                        10.9    35.9    7.30    1.34    0.97    0.92    9.71    37.5   0.13    0.90    32.1
  **2**    D-His                          0.09                                        43      1.13    12.3    0.12    4.38    0.71    12.5    24.7   0.090   2.37    14.1
  **3**    L-Phe                          0.07                                        0.013   34.7    36.3    9.81    10.45   10.93   16.3    1.38   1.02    0.24    33.4
  **4**    D-Phe                          86                                          0.035   15.4    49.3    4.63    0.072   9.74    9.30    0.37   0.051   7.21    9.5
  **5**    L-DOPA                         3.1                                         11.4    13.5    15.3    0.036   0.063   58.3    51.3    1.67   43      12.1    6.5
  **6**    D-DOPA                         4.9                                         7.8     28.7    34.7    4.59    3.71    34.7    54.7    0.89   0.73    36.8    4.0
  **7**    L-Trp                          44                                          27      20.5    37.1    1.13    0.89    57.5    37.5    26.0   16      16.5    13.5
  **8**    D-Trp                          41                                          12      19.0    39.6    1.24    1.35    39.6    43.6    28.1   0.81    18.0    8.7
  **9**    L-Tyr                          0.02                                        0.011   34.1    25.1    2.45    0.044   20.3    25.3    25.8   --      21.8    8.9
  **10**   D-Tyr                          0.04                                        0.013   --      --      --      --      --      --      --     --      --      --
  **11**   4-H~2~N-L-Phe                  0.24                                        0.15    43.2    0.079   2.76    2.17    18.7    48.7    1.09   --      2.90    16.3
  **12**   Histamine                      2.1                                         125     36.9    25.3    0.010   3.52    37.5    35.1    27.9   4.6     0.010   18.5
  **13**   Dopamine                       13.5                                        9.2     33.2    30.9    0.13    7.85    0.89    0.92    0.67   27      14.6    7.1
  **14**   Serotonin                      45                                          50      0.78    3.14    6.33    0.11    0.93    33.1    0.30   0.51    6.5     7.5
  **15**   2-Pyridyl-methylamine          26                                          34      1.03    5.19    23.56   0.24    43.7    1.07    41.5   3.8     21.7    11.6
  **16**   2--(2-Aminoethyl)pyridine      13                                          15      1.10    7.13    7.62    0.094   27.8    0.013   0.69   46      6.9     11.9
  **17**   1--(2-Aminoethyl)-piperazine   7.4                                         2.3     0.32    24.9    6.04    0.91    32.5    0.009   48.3   54      18.3    10.4
  **18**   4--(2-Aminoethyl)morpholine    0.14                                        0.19    0.091   1.30    0.089   1.15    64.3    0.43    0.24   0.013   5.4     9.3
  **19**   L-Adrenaline                   0.09                                        96      36.4    45.0    --      --      --      60      0.87   --      36.1    6.9

Mean from 3 different determinations (errors in the range of 5--10% of the reported values.

Compounds **1--19** generally activated, these CA isoforms in a very different manner based on their structures. Nanomolar potencies were observed for several isozymes. For example, hCA I was activated by compounds **1** (L-His), **2** (D-His), **3** (L-His), **9** (L-Tyr), **10** (D-Tyr), and **19** (L-adrenaline) with K~A~s ranging from 20 to 90 nM. The best activation profile was observed against one of the most abundant cytosolic isoform hCA II with K~A~s ranging from 125 µM to 11 nM. Specifically, compounds **3** (L-His), **9** (L-Tyr), and **10** (D-Tyr) showed good activation potency with K~A~s of 13, 11 and 13 nM, respectively. Other cytosolic isoforms hCA III and hCA VII were weakly activated, in general, by these series of amines and amino acids **1--19**. The remaining cytosolic isoform mCA XIII was moderately activated by most of the compounds with K~A~s ranging from 0.24 to 48.3 µM. Among the mitochondrial isoforms hCA VB was slightly better activated than hCA VA by these amines and amino acids. Interestingly, compound **5** (L-DOPA) showed nanomolar potency against both isozymes, hCA VA and VB, with K~A~s of 36 and 63 nM, respectively. Only one compound **11** (4-H~2~N-L-Phe) had nanomolar activity against membrane-bound isoform hCA IV with a K~A~ of 79 nM. On the other hand, another transmebrane-bound tumor overexpressed isoform hCA IX was moderately activated by most of the tested compounds, except the compound **16** and **17** which showed one of the best activation profile from the [Table 1](#t0001){ref-type="table"} with K~A~s of 13 and 9 nM, respectively. The CA activating effects of amines and amino acids **1--19** on the remaining membrane-bound isoforms hCA XII, hCA XIV and mCA XV were moderate to weak and most of the results were very close the each others ([Table 1](#t0001){ref-type="table"}).

3.. Activation of β-CAs with amino acids and amines {#s0003}
===================================================

In literature, there are many β-CAs which were investigated in details, among which Cab (from *Methanobacterium thermoautotrophicum*), scCA (from *Saccharomyces cerevisiae*), CgCA (from *Candida glabrata*), MgCA (from *Malassezia globosa*), VchCAβ (from *Vibrio cholerae*, mtCA 3 (from *Mycobacterium tuberculosis*), BsuCA1 (from *Brucella suis*), FtuCA (from *Francisella tularensis*), LdcCA (from *Leishmania donovani chagasi*), and EhiCA (from *Entameba histolytica*). Their activation by by amines and amino acid derivatives was investigated in the last several years \[[@CIT0031]\] -- [Table 2](#t0002){ref-type="table"}. In general, good to moderate activation effects were obtained against all β-CAs, except FtuCA, by using amino acid and amine derivatives **1--19**. Among the β-CAs, the best activation profile was observed against LdcCA, for which two compounds, **16** and **17**, showed nanomolar potency, with K~A~s of 12 and 9 nM, respectively. Interestingly, these two compounds have (2-aminoethyl) groups in their structures. Other interesting results were obtained against scCA for which the activation profile was better with amines (K~A~s: 0.95--21.3 µM) than with amino acids (K~A~s: 82--91 µM). Furthermore, VchCAβ and BsuCA1 was also activated efficiently, with K~A~s of 0.18--20.3 and 0.70--43.1 µM, by amino acids and amines, respectively. Specifically, VchCAβ was activated slightly more effectively by amines (K~A~s: 0.18--12.8 µM) than by amino acid derivatives (K~A~s: 0.94--20.3 µM). For BsuCA1 activities of most compounds are close to each other, except the compounds **2**, **8**, and **17** with K~A~s of 12.3, 13.7 and 43.1 µM, respectively, which are the least effective CAAs. In the case of FtuCA, most of the amines and amino acid derivatives (compounds **5**, **9--14**, **16**, **18** and **19**) investigated so far showed weak activation effects, with activation constants \>100 µM. The remaining activators were also moderately active against FtuCA, with K~A~s ranging between 30.5 to 78.3 µM. Other β-CAs (Cab, CgCA, MgCA, mtCA 3 and EhiCA) were activated in a different manner, as seen from [Table 2](#t0002){ref-type="table"}, with most of the activation constants in a limited range of values.

###### 

*In vitro* β-CA (Cab \[[@CIT0031]\], scCA \[[@CIT0031]\], CgCA \[[@CIT0034]\], MgCA \[[@CIT0032]\], VchCAβ \[[@CIT0035]\], mtCA 3 \[[@CIT0036]\], BsuCA1 \[[@CIT0037]\], FtuCA \[[@CIT0037]\], LdcCA \[[@CIT0038], [@CIT0039]\], and EhiCA \[[@CIT0038]\]) activation data with amines and amino acids (**1--19**).

                                          K~A~ (µM)[^a^](#TF2){ref-type="table-fn"}                                                             
  -------- ------------------------------ ------------------------------------------- ------ ------ ------ ------ ------ ------ ------- ------- -------
  **1**    L-His                          69                                          82     37     29.3   20.3   18.2   1.76   40.7    8.21    78.7
  **2**    D-His                          57                                          85     21.2   18.1   18.0   32.5   12.3   78.3    4.13    9.83
  **3**    L-Phe                          70                                          86     24.1   34.1   15.4   30.6   1.16   69.1    9.16    16.5
  **4**    D-Phe                          10.3                                        86     15.7   10.7   5.12   44.1   1.21   75.0    3.95    10.1
  **5**    L-DOPA                         11.4                                        90     23.3   8.31   8.36   30.0   2.07   \>100   1.64    16.6
  **6**    D-DOPA                         15.6                                        89     15.1   13.7   6.27   9.74   2.34   44.8    5.47    4.05
  **7**    L-Trp                          16.9                                        91     22.8   10.1   4.18   8.98   1.25   34.1    4.02    5.24
  **8**    D-Trp                          41                                          90     12.1   12.5   5.89   43.7   13.7   30.5    6.18    4.95
  **9**    L-Tyr                          10.5                                        85     9.5    15.7   6.15   28.9   1.38   \>100   8.05    4.52
  **10**   D-Tyr                          19.2                                        84     7.1    25.1   0.94   17.6   0.95   \>100   1.27    1.07
  **11**   4-H~2~N-L-Phe                  89                                          21.3   31.6   13.4   7.21   40.5   1.18   \>100   15.9    8.12
  **12**   Histamine                      76                                          20.4   27.4   10.9   9.50   34.2   3.71   \>100   0.74    7.38
  **13**   Dopamine                       51                                          13.1   27.6   9.43   1.24   12.1   1.54   \>100   0.81    30.8
  **14**   Serotonin                      62                                          15.0   16.7   14.2   1.37   10.3   4.26   \>100   0.62    4.94
  **15**   2-Pyridyl-methylamine          18.7                                        16.2   15.0   6.12   0.18   43.3   1.62   46.3    0.23    \>100
  **16**   2--(2-Aminoethyl)pyridine      40                                          11.2   16.3   7.30   1.00   45.9   5.20   \>100   0.012   \>100
  **17**   1--(2-Aminoethyl)-piperazine   13.8                                        9.3    14.9   0.81   0.24   50.3   43.1   51.8    0.009   43.8
  **18**   4--(2-Aminoethyl)morpholine    18.5                                        10.2   10.1   5.82   12.8   52.0   9.56   \>100   0.94    \>100
  **19**   L-Adrenaline                   11.5                                        0.95   10.8   0.72   8.73   52.2   0.70   \>100   4.89    25.6

Mean from 3 different determinations (errors in the range of 5--10% of the reported values, data not shown).

4.. Activation of γ-, δ-, ζ-, and η-CAs with amino acids and amines {#s0004}
===================================================================

Activation studies were also performed recently against γ-CAs, such as Zn-Cam and Co-Cam (from the Archaeon *Methanosarcina thermpophila*), BpsγCA (from the pathogenic bacterium *Burkhalderia pseudomallei*), PhaCA (from the cyanobacterium *Pseudoalteromonas haloplanktis*), and CpsCA (from another cyanobacteriu, *Colwellia psychrerythraea*), as well as δ-CAs, such as TweCAδ (from the diatom *Thalassiosira weissflogii*)\], ζ-CA, such as ZnTweCAζ (from the same diatom, *Thalassiosira weissflogii*)\], and η-CAs, such as PfaCA (from *Plasmodium falciparum*) \[[@CIT0031], [@CIT0040]\]. Among them, an interesting activation profile was observed for some of the γ- class CAs, such as BpsγCA. Most of the tested compounds showed nanomolar potency against this enzyme. Specifically, BpsγCA was efficiently activated by compounds **2**, **5**, **8**, **11**, **13**, and **16--19** with activation constants ranging between 9 to 86 nM. Interestingly, the ζ- class CA, ZnTweCAζ was activated slightly more efficiently by amines (K~A~s of 92 nM to 10.1 µM) than by amino acids (K~A~s of 0.62 to 15.4 µM), which is just the opposite in the case of the η- class CA PfaCA, for which K~A~s ranging from 0.12 to 8.55 µM were obtained for amino acid derivatives and between 0.71 and 9.97 µM for amines ([Table 3](#t0003){ref-type="table"}). A wide range of activities of the various activators for the remaining CAs was observed, such as for γ- class of CAs, Co-Cam and PhaCA, which were moderately activated by amino acid derivatives and amines with K~A~s of 0.72--135 µM ([Table 3](#t0003){ref-type="table"}). Other γ-CAs, such as Zn-Cam and CpsCA were less prone to be activated, as compared to other γ- CAs investigated so far, with activation constants ranging between 4.79 to \>100 µM. The unique δ- class CA investigated in details at this moment, TweCAδ, was efficiently activated by most of the amino acid derivatives and amines *1--19*, with K~A~s ranging between 51 nM and 18.9 µM.

###### 

*In vitro* γ-CA (Zn-Cam \[[@CIT0031]\], Co-Cam \[[@CIT0031]\], BpsγCA \[[@CIT0040]\], PhaCA \[[@CIT0041]\], and CpsCA \[[@CIT0041]\]), δ-CA (TweCAδ) \[[@CIT0042]\], ζ-CA (ZnTweCAζ) \[[@CIT0043]\], and η-CA (PfaCA) \[[@CIT0044]\] activation data with amines and amino acids (**1--19**).

                                          K~A~ (µM)[^a^](#TF3){ref-type="table-fn"}                                                 
  -------- ------------------------------ ------------------------------------------- ------ ------- ------ ------- ------- ------- ------
  **1**    L-His                          68                                          135    24.7    12.6   47.5    0.75    0.81    1.06
  **2**    D-His                          46                                          73     0.086   9.41   35.9    4.90    7.16    2.19
  **3**    L-Phe                          68                                          70     1.73    15.8   \>100   2.15    15.4    0.43
  **4**    D-Phe                          42                                          24     0.13    3.19   15.4    1.96    9.63    0.75
  **5**    L-DOPA                         39                                          38     0.072   1.08   4.79    2.11    3.19    0.12
  **6**    D-DOPA                         37                                          41     0.98    0.72   11.2    6.24    2.87    0.39
  **7**    L-Trp                          38                                          47     0.43    7.12   21.3    0.93    8.54    5.21
  **8**    D-Trp                          33                                          68     0.052   13.9   36.8    0.69    1.79    8.47
  **9**    L-Tyr                          24                                          53     0.20    1.02   19.5    1.52    0.98    1.02
  **10**   D-Tyr                          --                                          --     32.8    7.35   18.4    0.051   0.62    8.55
  **11**   4-H~2~N-L-Phe                  72                                          22     0.009   3.27   17.2    18.9    7.90    1.00
  **12**   Histamine                      63                                          9.2    0.12    6.48   20.6    1.34    1.27    9.86
  **13**   Dopamine                       54                                          18.4   0.014   8.70   32.1    0.51    10.1    9.97
  **14**   Serotonin                      38                                          0.97   0.10    9.05   34.8    0.90    3.06    7.18
  **15**   2-Pyridyl-methylamine          11.4                                        8.7    2.36    2.39   21.5    5.28    0.88    3.69
  **16**   2--(2-Aminoethyl)pyridine      24                                          18.5   0.034   18.7   38.2    8.16    0.85    6.75
  **17**   1--(2-Aminoethyl)-piperazine   10.1                                        16.1   0.018   15.1   33.0    4.37    0.12    0.71
  **18**   4--(2-Aminoethyl)morpholine    45                                          38     0.015   10.1   34.2    7.39    0.15    5.33
  **19**   L-Adrenaline                   39                                          8.9    0.019   17.5   79.8    2.43    0.092   2.40

Mean from 3 different determinations (errors in the range of 5--10% of the reported values, data not shown).

5.. Conclusions and future perspective {#s0005}
======================================

To our knowledge, this is the first article that summarizes the activation profile of all classes of CAs (the α-, β-, γ-, δ-, ζ-, and η-CA) with a small library of amines and amino acid derivatives. This panel of investigated amino acids and amines showed considerable activating properties, with a well defined structure--activity relationship, but without net differences between the various CA families. Even if the available activators are not isoform-selective (for the many α-CAs of human or other origins), as already mentioned above, in the last period, their possible use as pharmacological agents for memory therapy or for artificial tissues engineering started to be explored \[[@CIT0023],[@CIT0024]\], with very promising results being obtained. There is however a stringent need for having more effective, isoform-selective and possibly non-autacoid or amino acid derived compounds, which may possess a rather complicated polypharmacology \[[@CIT0003]\]. Furthemore, the investigations of the activating effects of non-human CAs are still in their infancy, with very few *in vitro* studies being available on the non-α-CA activators. Indeed, only in the few several years the first activation studies of β-, γ-, δ-, ζ-, and η-CAs from various organisms have been reported, which allowed the identification of compounds active in the nanomolar to micromolar range. However, no drug design studies of CAAs targeting these enzymes were performed so far, which is one of the future objectives of research in this area. In addition, almost nothing is known regarding the *in vivo* effects of CAAs in organisms other than the vertebrates (human and rodents). As briefly mentioned, many pathogenic bacteria, fungi or protozoans live in various niches which are potentially rich in endogenous activators of the amine and amino acid type. A deep understanding of the role that these modulators of activity may play in the interaction between the host and the pathogen, may lead to relevant biomedical discoveries, but this is an entire new field to be explored in the future.
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